In a terse bulleted statement, Globeimmune Inc. disclosed what sounded like its death knell: dissolution of its license agreement with Gilead Sciences Inc. for hepatitis B virus (HBV) candidate GS-4774, wholesale resignation of the company's CEO and board and termination of its office and manufacturing space.